A serological study was undertaken to investigate infections in active-duty United States soldiers with illnesses characterized by prolonged, afebrile, nonproductive coughs. Fifty-four soldiers were enrolled with such illness of у2 weeks' duration (case patients) along with 55 well soldiers (control subjects). Serum samples were tested for IgG and IgA antibody to 3 Bordetella pertussis antigens, pertussis agglutinins, IgM antibodies to Mycoplasma pneumoniae, IgM and IgG antibodies to Chlamydia pneumoniae, and IgM antibody to adenoviruses. Fortysix case patients (85%) had evidence of recent infection with Bordetella species, M. pneumoniae, or C. pneumoniae, and many had evidence of mixed infections; there were 27 Bordetella species, 20 C. pneumoniae, and 33 M. pneumoniae recent infections. Fifteen case patients had high titers of IgG or IgA to B. pertussis filamentous hemagglutinin without high titers of antibodies to other B. pertussis antigens, which suggested the presence of cross-reacting antibodies to M. pneumoniae and perhaps C. pneumoniae or unidentified infectious agent or agents. Since illnesses due to Bordetella species, M. pneumoniae, and C. pneumoniae can all be treated with macrolide antibiotics and B. pertussis illness can be prevented by immunization, and since military readiness was affected in 63% of the cases, it seems important to conduct further studies in military populations.
Respiratory tract infections are common among members of the United States armed forces [1] [2] [3] . The spectrum of respiratory tract infection may range from frank pneumonia-with fever, rales, and sputum production-to minor symptoms, limited to either cough without fever or else sputum production and a clear chest on auscultation.
In February 1997, 1 of us (J.M.V.) provided medical support to the US Army soldiers on a field exercise with the Second Infantry Division at Camp Casey, South Korea. The most com- mon complaint at sick call during this exercise was prolonged nonproductive cough in afebrile soldiers. The duration of symptoms ranged from 2 to 6 weeks before medical care was sought. Soldiers often described their cough as paroxysmal, and many soldiers had posttussive emesis and/or displayed subconjunctival hemorrhages.
In light of a number of recent studies, these findings suggested the possibility that these illnesses were due to Bordetella pertussis infections [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . However, findings in recent pertussis vaccine efficacy trials and other epidemiological studies have led to some concern on our part as to the specificity of the serological diagnosis of B. pertussis infection with use of some B. pertussis antigens [4, 14] . We also have become interested in the possibility of mixed infections with B. pertussis and other infectious agents.
Since illness with chronic cough is a significant and, possibly, preventable problem in frontline military personnel, we performed the present investigation to look for serological evidence of B. pertussis, Mycoplasma pneumoniae, Chlamydia pneumoniae, and adenovirus infections in active-duty United States soldiers with illnesses characterized by prolonged, afebrile, nonproductive coughs. 
Methods
Subjects. Active-duty United States Army soldiers stationed with the Second Infantry Division in Korea who were afebrile, had nonproductive cough illnesses of у2 weeks' duration (case patients), and sought medial care were asked to participate. Control subjects were well, age-matched, active-duty US Army soldiers at the 25th Infantry Division (Light) at Schofield Barracks in Hawaii. Following informed consent, all case patients and control subjects completed questionnaires, and single blood samples were obtained.
Serological studies. IgA and IgG antibodies to B. pertussis antigens-pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (pertactin)-were determined by ELISA, as described elsewhere, except that the reference-line computer program was used rather than the parallel-line method [4, 6, 10, 15] . Agglutinin titers were determined by use of BP 460 as the antigen [4, 16] . M. pneumoniae IgM antibody titers were determined qualitatively by ELISA (Immuno Card Mycoplasma; Meridian Diagnostics, Cincinnati, OH). C. pneumoniae IgM and IgG antibodies were determined by immunofluorescence assay, as described elsewhere [17] . Adenovirus IgM antibodies to a group antigen were determined by immunofluorescence assay at the Viral and Rickettsial Disease Laboratory of the California State Department of Health Services (Berkeley, CA).
Serological evidence of recent infection in case patients included the presence of IgM antibody to M. pneumoniae, C. pneumoniae, or adenovirus; a C. pneumoniae IgG titer у512 [17] ; and an ELISA value of IgA or IgG antibodies to PT, FHA, or pertactin that was in the у95th percentile of the control group or an agglutinin titer that was in the у95th percentile of the control group [4, 6] . There were too few control sera with measurable PT or pertactin IgA antibody to accurately determine the 95th percentile value, so IgA PT or pertactin values were not used for the determinations of recent infection.
To qualitatively assess the antibodies present in sera from selective case patients, we used western blot analysis with whole cell lysates of B. pertussis and M. pneumoniae as antigens. Comparisons were made with blot patterns of sera from patients with cultureconfirmed B. pertussis infection.
Statistical analysis. P values for comparing proportions between groups were computed by means of the x 2 test. Exact P values were calculated by use of STATXACT-3 software (Cytel Software, Cambridge, MA). P values for comparing medians were computed by use of the Wilcoxon rank-sum test of the Student's t test when the log scale distribution was well modeled by a Gaussian distribution.
Results

Clinical.
Fifty-four patients with qualifying cough illnesses (case patients) were recruited from 15 July 1997 through 23 April 1998, and 55 age-matched well subjects (control subjects) were enrolled on 8 June 1998. Seventy percent of the case patients and 73% of the control subjects were men, and 36% and 33% of the case patients and control subjects, respectively, were smokers. Sixty percent of the case patients worked in an enclosed area (such as an enclosed military vehicle), whereas only 11% of the control subjects had a similar work environment ( The percentage of case patients and control subjects with measurable antibody to B. pertussis antigens is presented in table 2, and the frequency distributions of these antibodies between case patients and control subjects are presented in figure 1. Median and percentile comparisons of antibody values in case patients and control subjects are presented in table 3. As can be seen in table 2, the majority of case patients and control subjects had measurable IgG antibody to PT and FHA, and they also had agglutinins. Few subjects had measurable IgA antibody to PT and pertactin. As can be seen in figure 1 and  table 3 , the distribution of antibody between case patients and control subjects was similar, except for antibody to FHA. Case patients had significantly higher median values of IgA and IgG to FHA than did control subjects, and 35% of the IgG values in the case patients were above the 95th percentile for the control subjects.
C. pneumoniae antibody. One case patient and no control subjects had measurable IgM antibody to C. pneumoniae, whereas 83 (76%) of case patients and control subjects had IgG antibody to this organism. The frequency distribution of IgG antibodies to C. pneumoniae in case patients and control subjects is presented in figure 2 . C. pneumoniae IgG antibody titers у512 or detectable IgM antibody were found in 20 (37%) of case patients but in only 9 (16%) of control subjects ( ). P = .03 M. pneumoniae antibodies. M. pneumoniae IgM antibody was detected in sera from 33 (61%) of the case patients but in sera from only 17 (31%) of control subjects ( ). P = .002 Adenovirus antibodies. Adenovirus IgM antibodies were noted in 3 (5%) of case patients and control subjects. All 3 case patients with adenovirus IgM antibody also were M. pneumoniae IgM-positive, and 2 of these 3 also had C. pneumoniae IgG titers у512. Western blot analysis revealed that all sera contained antibodies that at least weakly recognized polypeptides in both B. pertussis and M. pneumoniae lysates, a finding suggesting the presence of cross-reacting antibodies and/or low levels of antibodies induced by prior immunization or exposure. Unlike sera from patients recovering from culture-positive B. pertussis infection, sera containing high levels of antibody to FHA without elevated PT, pertactin, or agglutinin titers did not react more strongly with B. pertussis antigens than with M. pneumoniae antigens.
Relationship of working in an enclosed space to specific antibodies in case patients. Sixty percent of case patients and 11% of control subjects worked in an enclosed space. However, of the case patients, those who worked in enclosed spaces were no more likely to have high titers of IgG antibodies to FHA (у95th percentile for control patients), to be M. pneumoniae IgM-seropositive, or to have high titers of C. pneumoniae IgG antibody (у95th percentile for control patients) than those who did not work in an enclosed space.
Discussion
The classic method for serological diagnosis of an illness due to an infectious agent was the demonstration of an antibody titer increase in paired acute-and convalescent-phase sera. Classically, it was also noted that the demonstration of high antibody titers could indicate acute infection. More recently, the presence of IgM or IgA antibodies in the sera of patients with illness has been used as an indication of causation. However, high single antibody values and the presence of IgM and IgA antibodies indicate some recent infection, but not necessarily the illness being studied.
In epidemiological studies, the utility of high single antibody values and of the presence of IgA and IgM antibodies has been repeatedly demonstrated [4-6, 8, 9, 13, 17] . In a study of prolonged cough illnesses in university students, it was shown that the patterns of antibody to B. pertussis antigens were different in case patients and control subjects and that the sensitivity and specificity of different cut-off values could be determined based on data from the control patients. Using high single values or significant increases in titers of antibody to у1 B. pertussis antigens, investigators in a number of studies have suggested that 12%-32% of prolonged cough illnesses in adults are due to B. pertussis infection [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . However, all of these studies may have included false-positive cases, which could be due to (1) statistical chance, because of multiple comparisons; (2) cross-reacting antibodies to known or unknown infectious agents; and (3) polyclonal antibody responses induced by a variety of infectious agents.
In this trial, we found that the antibody patterns for FHA IgG and IgA, the M. pneumoniae IgM and IgG, and the C. pneumoniae IgG were different in case patients than they were in control subjects. The selection of a control group in this study was problematic. If the control group was closely associated with the case group, then overmatching might occur and true findings might not be uncovered. On the other hand, a totally unrelated control group could lead to meaningless positives in 1 of the 2 groups. On the basis of these considerations, we matched for age but chose control subjects from Army infantry personnel in Hawaii rather than in Korea, because all personnel in Korea were closely associated with the sick personnel.
On the basis of the study enrollment criteria and the findings noted in table 1, the 54 case patients in this investigation all had illnesses suggestive of adult pertussis. However, even though 50% of the case patients had a high value of antibody to у1 B. pertussis antigens, the antibody patterns suggest that few of the illnesses were due to B. pertussis infection. We found elevated values of IgG or IgA antibody to FHA in 15 case patients without elevated values of antibody to PT, pertactin, or agglutinins, which is not consistent with a diagnosis of B. pertussis as the cause of the illness.
Other Bordetella species (Bordetella parapertussis and Bordetella bronchiseptica) also have FHA similar to B. pertussis FHA and, when they produce infection, are associated with increases in titer of antibody to B. pertussis FHA. Therefore, it is possible that the single increases we found were the result of non-pertussis Bordetella species. However, the other Bordetella species also have outer-membrane proteins that cross-react with B. pertussis pertactin. Therefore, if the illnesses in these 15 case patients were due to other Bordetella species, high values of antibody to pertactin should also have been noted.
On the basis of these observations, we consider it likely that most of the case patients with significant values of IgA or IgG antibody to FHA did not have Bordetella species infections. The B. pertussis antibody data suggest that 11 case patients (20%) had Bordetella species infections (high values of antibody to PT or FHA and pertactin or agglutinins), and of these 11 patients, 4 (7%) had B. pertussis infections (high values of antibody to PT). The C. pneumoniae, M. pneumoniae, and adenovirus antibody data suggest that 20 (37%), 33 (61%), and 3 (5%) of the case patients, respectively, had recent infections with these agents, and some of these were mixed infections.
Of most interest is the combination of antibody data presented in table 4. These data suggest the possibility of mixed infections, successive infections, cross-reacting antibodies, or combinations of the 3 variables. In children, mixed B. pertussis and adenovirus infections have been commonly observed, and, in a previous study, 3 of 4 young adults with M. pneumoniae infections also had significant titer increases or high values of antibody to B. pertussis antigens [4, 18] . M. pneumoniae has a number of glycolipid and glycoprotein antigens, antibodies that react to a number of other infections and noninfectious agents [19] . Antibody to B. pertussis FHA cross-reacts with other Bordetella species and perhaps with nontypeable Haemophilus influenzae, Escherichia coli, and Vibrio cholerae [12] .
In addition, our western blot data support the hypothesis that elevated FHA antibody values alone are not necessarily consistent with or indicative of B. pertussis illness. Antibody to B. pertussis pertactin also cross-reacts with the similar outermembrane protein of B. parapertussis [14] . Finally, Høiby et al. have presented data showing that 2 B. pertussis antigens crossreacted with many other bacterial species [20] . These other bacteria were mainly gram-negative species and included Neisseria meningitidis, Pasteurella multocida, Salmonella typhi, Shigella sonnei, Yersinia enterocolitica, and Pseudomonas aeruginosa.
It is likely that some of our combination-antibody data indicate sequential infections and that others indicate mixed infections. It is also likely that some of the FHA high-titer/IgM M. pneumoniae combinations represent M. pneumoniae infections with cross-reacting antibodies. It also seems likely that the single high FHA values are due to infections with other agents yet to be identified, rather than with the known crossreacting species, because these latter agents typically have not caused prolonged cough illnesses.
In spite of the concerns noted above that statistical factors and cross-reacting antibodies may have yielded some false-positives, it appears that an etiology was determined for a substantial number of the illnesses in the 54 case patients. Fortyone (76%) had evidence of recent infections with Bordetella species, M. pneumoniae, or C. pneumoniae. Illnesses due to all 3 infectious agents are treatable with macrolide antibiotics, and B. pertussis infections in all likelihood can be prevented by the use of booster immunization programs with adult acellular pertussis vaccines.
Since military readiness was affected for 63% of the case patients, our data suggest that further studies in military populations should be undertaken. In addition to surveillance and clinical data, acellular pertussis vaccine trials should be con-sidered, as well as selected studies of macrolide treatment and prophylaxis.
